RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Rallybio Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.35+0.07 (+0.43%)
Close on Oct 19, 2026
- Market cap
- $94.80M
- P/E (TTM)
- 2.1
- Dividend yield
- –
Rallybio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Rallybio | Industry median |
|---|---|---|
| Market Cap | $86.83M | $166.30M |
| Enterprise Value | -$5.97M | $88.19M |
| PE Ratio | 2.06 | 20.44 |
| PS Ratio | 134.41 | 3.65 |
| PB Ratio | 0.92 | 2.03 |
| P/TBV Ratio | 0.92 | 2.29 |
| P/OCF Ratio | 3.25 | 12.98 |
Enterprise value
| Measure | Rallybio | Industry median |
|---|---|---|
| EV / Sales | -9.25 | 2.51 |
Income (trailing twelve months)
| Measure | Rallybio | Industry median |
|---|---|---|
| Revenue | $646.00K | $58.34M |
| Operating Income | -$27.72M | -$21.40M |
| Pretax Income | $46.00M | -$14.34M |
| Net Income | $45.55M | -$22.46M |
| EBITDA | -$27.68M | -$16.91M |
| EPS (Diluted) | $7.92 | -$0.83 |
Margins
| Measure | Rallybio | Industry median |
|---|---|---|
| Operating Margin | -4291.5% | -44.0% |
| Pretax Margin | 7120.9% | -13.3% |
| Profit Margin | 7051.2% | -40.2% |
| EBITDA Margin | -4284.8% | -30.2% |
Returns
| Measure | Rallybio | Industry median |
|---|---|---|
| Return on Equity (ROE) | 64.9% | -53.2% |
| Return on Assets (ROA) | 61.1% | -40.9% |
| Return on Invested Capital (ROIC) | -2234.8% | -32.4% |
| Return on Capital Employed (ROCE) | -29.3% | -38.1% |
Growth
| Measure | Rallybio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -15.1% | 5.96% |
Balance sheet
| Measure | Rallybio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $92.80M | $61.43M |
| Net Cash (Debt) | $92.80M | $15.35M |
| Net Cash Per Share | $17.47 | $0.66 |
| Equity (Book Value) | $94.50M | $49.09M |
| Book Value Per Share | $17.79 | $1.37 |
| Tangible Book Value | $94.50M | $23.52M |
| Working Capital | $93.69M | $76.81M |
Financial position
| Measure | Rallybio | Industry median |
|---|---|---|
| Current Ratio | 27.26 | 3.34 |
| Quick Ratio | 26.02 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Rallybio | Industry median |
|---|---|---|
| Operating Cash Flow | $26.71M | -$12.35M |
Efficiency
| Measure | Rallybio | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.39 |
| Revenue Per Employee | $46.14K | $404.87K |
| Profits Per Employee | $3.25M | -$703.34K |
| Employee Count | 14 | 74 |
Dividends and yields
| Measure | Rallybio | Industry median |
|---|---|---|
| Earnings Yield | 52.5% | -23.3% |
Shares
| Measure | Rallybio | Industry median |
|---|---|---|
| Shares Outstanding | 5,310,500 | 58,127,000 |
| Shares Change (YoY) | 1.97% | 10.9% |
| Shares Change (QoQ) | 0.31% | 0.54% |
| Float | 747,068 | 49,136,700 |
| Shares Held by Insiders | 85.9% | 11.6% |
Scores
| Measure | Rallybio | Industry median |
|---|---|---|
| Graham Number | $56.31 | $18.73 |
| Graham Upside | 244.4% | -45.1% |
| Altman Z-Score | 11.02 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Rallybio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.